Average Co-Inventor Count = 3.04
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Beigene, Ltd. (14 from 52 patents)
2. Microsoft Technology Licensing, LLC (2 from 54,638 patents)
3. Beigene Switzerland Gmbh (1 from 22 patents)
17 patents:
1. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist
2. 11534431 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
3. 11472811 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
4. 10882856 - 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
5. 10864203 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
6. 10647714 - 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases
7. 10576087 - Fused tricyclic compounds as Raf kinase inhibitors
8. 10562899 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
9. 10351559 - Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
10. 10280163 - 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases
11. 10208038 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
12. 9920055 - Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
13. 9895376 - Fused tricyclic compounds as Raf kinase inhibitors
14. 9670203 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
15. 9273046 - Fused tricyclic compounds as Raf kinase inhibitors